利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

48 条记录 (耗时 0.036 秒)

    Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus
    21.
    发明授权
    Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus 失效
    环丙酰胺化合物及其类似物作为丙型肝炎病毒

    公开(公告)号：US08445430B2

    公开(公告)日：2013-05-21

    申请号：US12622753

    申请日：2009-11-20

    申请人： Suoming Zhang ,  Avinash Phadke ,  Milind Deshpande ,  Venkat Gadhachanda

    发明人： Suoming Zhang ,  Avinash Phadke ,  Milind Deshpande ,  Venkat Gadhachanda

    IPC分类号： A61K38/00 ,  A01N37/18

    CPC分类号： C07K5/0808 ,  C07K5/0819

    摘要： The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.

    摘要翻译： 本发明提供式I的环状羧酰胺化合物及其类似物及其药学上可接受的盐和水合物。 变量R，R1，R6-R8，R16，R18，R19，M，n，T，Y和Z在本文中定义。 某些式I化合物可用作抗病毒剂。 本文公开的某些环状羧酰胺化合物和环状羧酰胺类似物是有效和/或选择性的病毒复制抑制剂，特别是丙型肝炎病毒复制。 本发明还提供含有一种或多种环状羧酰胺化合物或环状甲酰胺类似物和一种或多种药学上可接受的载体的药物组合物。 这样的药物组合物可以含有环状羧酰胺化合物或环状羧酰胺类似物作为唯一的活性剂，或者可以含有环状羧酰胺化合物或环状甲酰胺类似物和一种或多种其它药学活性剂的组合。 本发明还提供了治疗病毒感染的方法，包括丙型肝炎感染。

    CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS
    22.
    发明申请
    CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS 失效
    周期性羧酰胺化合物及其与乙型肝炎病毒的模拟物

    公开(公告)号：US20100124545A1

    公开(公告)日：2010-05-20

    申请号：US12622753

    申请日：2009-11-20

    申请人： Suoming Zhang ,  Avinash Phadke ,  Milind Deshpande ,  Venkat Gadhachanda

    发明人： Suoming Zhang ,  Avinash Phadke ,  Milind Deshpande ,  Venkat Gadhachanda

    IPC分类号： A61K38/21 ,  A61K38/12 ,  A61K31/7056 ,  A61K31/47 ,  C07K5/12 ,  C07D215/233 ,  A61P31/12

    CPC分类号： C07K5/0808 ,  C07K5/0819

    摘要： The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof.The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.

    摘要翻译： 本发明提供式I的环状羧酰胺化合物及其类似物及其药学上可接受的盐和水合物。 变量R，R1，R6-R8，R16，R18，R19，M，n，T，Y和Z在本文中定义。 某些式I化合物可用作抗病毒剂。 本文公开的某些环状羧酰胺化合物和环状羧酰胺类似物是有效和/或选择性的病毒复制抑制剂，特别是丙型肝炎病毒复制。 本发明还提供含有一种或多种环状羧酰胺化合物或环状甲酰胺类似物和一种或多种药学上可接受的载体的药物组合物。 这样的药物组合物可以含有环状羧酰胺化合物或环状羧酰胺类似物作为唯一的活性剂，或者可以含有环状羧酰胺化合物或环状甲酰胺类似物和一种或多种其它药学活性剂的组合。 本发明还提供了治疗病毒感染的方法，包括丙型肝炎感染。

    Azabenzofuran substituted thioureas; inhibitors of viral replication
    23.
    发明申请
    Azabenzofuran substituted thioureas; inhibitors of viral replication 失效
    氮杂苯并呋喃取代的硫脲; 病毒复制抑制剂

    公开(公告)号：US20050228013A1

    公开(公告)日：2005-10-13

    申请号：US11029910

    申请日：2005-01-05

    申请人： Andrew Thurkauf ,  Dawei Chen ,  Avinash Phadke ,  Shouming Li ,  Milind Deshpande

    发明人： Andrew Thurkauf ,  Dawei Chen ,  Avinash Phadke ,  Shouming Li ,  Milind Deshpande

    IPC分类号： A61K31/00 ,  A61K31/4355 ,  A61K31/4741 ,  A61K38/21 ,  C07D471/04 ,  C07D491/02 ,  C07D491/04

    CPC分类号： A61K31/00 ,  A61K31/4355 ,  C07D491/04

    摘要： The present invention provides compounds of Formula 1, wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W. X, and Y are defined herein. Certain compounds of Formula 1 described herein possess potent antiviral activity. The invention also provides compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

    摘要翻译： 本发明提供式1的化合物，其中变量Ar，A 1，A 2，A 3，A 4， R 5，R 6，R 7，V，W，X和Y如本文所定义。 某些本文所述的式1的化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式1化合物。 本发明还提供含有一种或多种式1化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效减少疾病体征或症状的式1化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染，特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。 治疗方法包括施用作为单一活性剂的式1化合物或与一种或多种其它治疗剂组合施用式1的化合物。

    Urea-containing peptides as inhibitors of viral replication
    24.
    发明授权
    Urea-containing peptides as inhibitors of viral replication 失效
    含尿素肽作为病毒复制的抑制剂

    公开(公告)号：US08163693B2

    公开(公告)日：2012-04-24

    申请号：US12236855

    申请日：2008-09-24

    申请人： Dawei Chen ,  Milind Deshpande ,  Avinash Phadke

    发明人： Dawei Chen ,  Milind Deshpande ,  Avinash Phadke

    IPC分类号： A61K38/00

    CPC分类号： C07K5/0823 ,  A61K38/00 ,  C07K5/06165

    摘要： The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables T, R1-R9, J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

    摘要翻译： 本发明提供式I化合物的含脲的肽化合物及其药用盐和水合物。 变量T，R1-R9，J，L，M，Y，Z，m，n和t在本文中定义。 某些式I化合物可用作抗病毒剂。 本文公开的某些含脲的肽化合物是病毒复制的有效和/或选择性抑制剂，特别是丙型肝炎病毒复制。 本发明还提供含有一种或多种含尿素的肽化合物和一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 这样的药物组合物可以含有含有肽化合物作为唯一活性剂的尿素，或者可以含有含尿素的肽化合物和一种或多种其它药学活性剂的组合。 本发明还提供了用于治疗哺乳动物中的病毒感染（包括丙型肝炎感染）的方法。

    UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
    25.
    发明申请
    UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION 失效
    作为病毒复制的抑制剂的尿素包含肽

    公开(公告)号：US20090082261A1

    公开(公告)日：2009-03-26

    申请号：US12236855

    申请日：2008-09-24

    申请人： Dawei Chen ,  Milind Deshpande ,  Avinash Phadke

    发明人： Dawei Chen ,  Milind Deshpande ,  Avinash Phadke

    IPC分类号： A61K38/12 ,  C07K14/00 ,  C07K7/06 ,  C07K7/50 ,  C07K5/08 ,  C07K5/10 ,  A61P31/12 ,  C07K5/12 ,  A61K38/21 ,  A61K38/08 ,  A61K38/06 ,  A61K38/07

    CPC分类号： C07K5/0823 ,  A61K38/00 ,  C07K5/06165

    摘要： The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof.The variables T, R1-R9, J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

    摘要翻译： 本发明提供式I化合物的含脲的肽化合物及其药用盐和水合物。 变量T，R1-R9，J，L，M，Y，Z，m，n和t在本文中定义。 某些式I化合物可用作抗病毒剂。 本文公开的某些含脲的肽化合物是病毒复制的有效和/或选择性抑制剂，特别是丙型肝炎病毒复制。 本发明还提供含有一种或多种含尿素的肽化合物和一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 这样的药物组合物可以含有含有肽化合物作为唯一活性剂的尿素，或者可以含有含尿素的肽化合物和一种或多种其它药物活性剂的组合。 本发明还提供了用于治疗哺乳动物中的病毒感染（包括丙型肝炎感染）的方法。

    Azabenzofuran substituted thioureas; inhibitors of viral replication
    26.
    发明授权
    Azabenzofuran substituted thioureas; inhibitors of viral replication 失效
    氮杂苯并呋喃取代的硫脲; 病毒复制抑制剂

    公开(公告)号：US07439374B2

    公开(公告)日：2008-10-21

    申请号：US11029910

    申请日：2005-01-05

    申请人： Andrew Thurkauf ,  Dawei Chen ,  Avinash Phadke ,  Shouming Li ,  Milind Deshpande

    发明人： Andrew Thurkauf ,  Dawei Chen ,  Avinash Phadke ,  Shouming Li ,  Milind Deshpande

    IPC分类号： C07D401/02 ,  A61K31/44

    CPC分类号： A61K31/00 ,  A61K31/4355 ,  C07D491/04

    摘要： The present invention provides compounds of Formula 1, wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W, X, and Y are defined herein. Certain compounds of Formula 1 described herein possess potent antiviral activity. The invention also provides compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

    摘要翻译： 本发明提供式1的化合物，其中变量Ar，A 1，A 2，A 3，A 4， R 5，R 6，R 7，V，W，X和Y在本文中定义。 某些本文所述的式1的化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式1化合物。 本发明还提供含有一种或多种式1化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效减少疾病体征或症状的式1化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染，特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。 治疗方法包括施用作为单一活性剂的式1化合物或与一种或多种其它治疗剂组合施用式1的化合物。

    NS5A inhibitors useful for treating HCV
    27.
    发明授权
    NS5A inhibitors useful for treating HCV 有权
    用于治疗HCV的NS5A抑制剂

    公开(公告)号：US08835456B1

    公开(公告)日：2014-09-16

    申请号：US13423935

    申请日：2012-03-19

    申请人： Jason Allan Wiles ,  Venkat Gadhachanada ,  Avinash Phadke ,  Milind Deshpande ,  Dawei Chen

    发明人： Jason Allan Wiles ,  Venkat Gadhachanada ,  Avinash Phadke ,  Milind Deshpande ,  Dawei Chen

    IPC分类号： A61K31/44 ,  C07D451/02

    CPC分类号： C07D471/08 ,  A61K45/06

    摘要： The invention provides compounds of Formula I and the pharmaceutically salts thereof. These compounds may be generally described as bridged-bicyclo indole-containing compounds. The variables shown in Formula I are defined herein. Certain compounds of Formula I are useful as antiviral agents. Compounds as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I and at least one pharmaceutically acceptable carrier. Such pharmaceutical compositions may contain a compound of Formula I as the only active agent or may contain a combination of a compound of Formula I and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.

    摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 这些化合物通常可以被描述为含桥连双环吲哚的化合物。 式I中所示的变量在本文中定义。 某些式I化合物可用作抗病毒剂。 本文公开的化合物是病毒复制的有效和/或选择性抑制剂，特别是丙型肝炎病毒复制。 本发明还提供含有一种或多种式I化合物和至少一种药学上可接受的载体的药物组合物。 这样的药物组合物可以含有式I化合物作为唯一的活性剂，或者可以含有式I化合物与一种或多种其它药物活性剂的组合。 本发明还提供了用于治疗患者中的病毒感染（包括丙型肝炎感染）的方法。